Radiotherapy and Temozolomide Non-Rresponsive Adult Spinal Cord Astrocytoma with a Good Response to Bevacizumab: A Case Report and Literature Review

Yıl 2021, Cilt: 16 Sayı: 1, 117 - 121, 08.02.2021

Ayşegül Üçüncü Kefeli Süleyman Halil

https://doi.org/10.17517/ksutfd.767351

Öz

The incidence of spinal cord astrocytomas (SCAs) is very low and therefore, management of these tumors are challenging due to this paucity. In this report, a patient with a recurrent SCA was successfully treated with bevacizumab after failing to previous therapies including radiotherapy (RT) and temozolomide (TMZ). Bevacizumab is an angiogenesis inhibitor that is widely used in high grade gliomas and shows promise for SCAs spinal cord astrocytomas but there is limited data about the usage of bevacizumab in SCAs. We herein add an important contribution to the literature by reporting a nearly total response to bevacizumab in a patient with low grade SCA.

Anahtar Kelimeler

bevacizumab, temozolomide, spinal cord astrocytoma

Destekleyen Kurum

-

Proje Numarası

-

Teşekkür

-

Bevasizumab’a İyi Cevap Veren, Radyoterapi ve Temozolomid Tedavisine Yanıtsız Bir Erişkin Spinal Kord Astrositomu; Olgu Sunumu ve Literatür Derlemesi

Öz

Spinal kord astrositomlarının (SKA) görülme sıklığı çok düşüktür ve bu insidans azlığı nedeniyle bu tümörlerin yönetimi zordur. Bu vakada, rekürren SKA'lı bir hastada, radyoterapi (RT) ve temozolomid (TMZ) dahil olmak üzere önceki tedavilerden fayda görmeyen bir hastada bevasizumab ile görülen iyi yanıtı bildirmekteyiz. Bevasizumab, yüksek dereceli gliomlarda yaygın olarak kullanılan ve spinal kord astrositomları için umut vaat eden bir anjiyojenez inhibitörüdür, ancak SKA'larda bevasizumab kullanımı hakkında sınırlı veri bulunmaktadır. Bu yazıda, düşük dereceli SKA'lı bir vakada bevasizumab ile tama yakın cevap bildirerek literatüre önemli bir katkı eklemekteyiz.

Anahtar Kelimeler

bevasizumab,, temozolomid, spinal kord astrositomu

Proje Numarası

-

Kaynakça

• 1. Tobin MK, Geraghty JR, Engelhard HH, Linninger AA, Mehta AI. Intramedullary spinal cord tumors: a review of current and future treatment strategies. Neurosurg Focus. 2015;39(2):E14.
• 2.Grimm S, Chamberlain MC. Adult primary spinal cord tumors. Expert Rev Neurother. 2009;9(10):1487-95.
• 3.Epstein FJ, Farmer JP, Freed D. Adult intramedullary astrocytomas of the spinal cord. J Neurosurg. 1992;77(3):355-59.
• 4.Fakhreddine MH, Mahajan A, Penas-Prado M, Weinberg J, McCutcheon IE, Puduvalli V, et al. Treatment, prognostic factors, and outcomes in spinal cord astrocytomas. Neuro Oncol. 2013;15(4):406-12.
• 5.Rodrigues GB, Waldron JN, Wong CS, Laperriere NJ. A retrospective analysis of 52 cases of spinal cord glioma managed with radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48(3):837–42.
• 6. Minehan KJ, Brown PD, Scheithauer BW, Krauss WE, Wright MP. Prognosis and treatment of spinal cord astrocytoma. Int J Radiat Oncol Biol Phys. 2009;73(3):727–33.
• 7.Abdel-Wahab M, Etuk B, Palermo J, Shirato H, Kresl J, Yapicier O, et al. Spinal cord gliomas: a multi-institutional retrospective analysis. Int J Radiat Oncol Biol Phys. 2006;64(4):1060–71.
• 8.Roonprapunt C, Houten JK. Spinal cord astrocytomas: presentation, management, and outcome. Neurosurg Clin N Am. 2006;17(1):29–36.
• 9.Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11(5):850–6.
• 10.Lefkowitz IB, Packer RJ, Sutton LN, Siegel KR, Bruce DA, Evans AE, et al. Results of the treatment of children with recurrent gliomas with lomustine and vincristine. Cancer. 1988;61(5):896–902.
• 11.Allen JC, Aviner S, Yates AJ, Boyett JM, Cherlow JM, Turski PA, et al. Treatment of highgrade spinal cord astrocytoma of childhood with ‘‘8-in-1’’ chemotherapy, radiotherapy: a pilot study of CCG-945. Children’s Cancer Group. J Neurosurg. 1998;88(3):215–20.
• 12.Lowis SP, Pizer BL, Coakham H, Nelson RJ, Bouffet E. Chemotherapy for spinal cord astrocytoma: can natural history be modified?. Childs Nerv Syst. 1998;14(7):317–21.
• 13. Chamberlain MC. Salvage chemotherapy for recurrent spinal cord ependymona. Cancer. 2002;95(5):997–1002.
• 14.Chamberlain MC. Temozolomide for recurrent low-grade spinal cord gliomas in adults. Cancer. 2008;113(5):1019–24.
• 15. Kim MS, Chung CK, Choe G, Kim IH, Kim HG. Intramedullary spinal cord astrocytoma in adults: postoperative outcome. J Neurooncol. 2001;52(1):85–94.
• 16.Kaley TJ, Mondesire-Crump I, Gavrilovic IT. Temozolomide or bevacizumab for spinal cord high-grade gliomas. J Neurooncol. 2012;109(2):385-89.
• 17.Chamberlain MC, Johnston SK. Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. J Neurooncol. 2011;102(3):427-32.
• 18. Gorsi HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, et al. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience. Pediatr Blood Cancer. 2018;65(9):e27234.
• 19.Gwak SJ, An SS, Yang MS, Joe E, Kim DH, Yoon DH, Kim KN, et al. Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor. Spine. 2014;39(2):e65-73.